1188266-11-6

Duloxetine-d₃ is intended for use as an internal standard for the quantification of duloxetine by GC- or LC-MS. (S)-Duloxetine is a potent inhibitor of serotonin and norepinephrine reuptake (K_is = 4.6 and 15.6 nM, respectively, for rat synaptosomes). It also inhibits dopamine reuptake (K_i = 369 nM). (S)-Duloxetine suppresses spontaneous firing activity in vivo in the dorsal raphe and locus coeruleus (ED₅₀s = 99 and 475 μg/kg, respectively). It also decreases immobility time and increases latency to first immobility in the forced swim test in mice when administered at doses of 16 and 32 mg/kg. Formulations containing (S)-duloxetine have been used in the treatment of major depressive disorder, generalized anxiety disorder, chronic neuropathic and musculoskeletal pain, and fibromyalgia.

Store at 4°C

[1] DAVID T. WONG PH.D. LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake[J]. Neuropsychopharmacology, 1993, 8 1: 23-33. DOI: 10.1038/npp.1993.4
[2] K KASAMO  C D M  P Blier. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain.[J]. Journal of Pharmacology and Experimental Therapeutics, 1996, 277 1: 278-286.
[3] VINCENT CASTAGNé  Paul M  Roger D Porsolt. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse[J]. European journal of pharmacology, 2009, 616 1: Pages 128-133. DOI: 10.1016/j.ejphar.2009.06.018